Company Description

Hybrid Bio is a pioneering biotechnology company developing a first-in-class myeloid cell therapy platform designed to overcome the fundamental limitations of today’s immuno-oncology treatments. By harnessing a rare and powerful immune cell type — Hybrid (APC-like) Neutrophils— they transform resistant solid tumors into curable diseases.